Drug treatments in Alzheimer's disease

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 16, Issue 3, 2016, Pages 247-253

  Briggs, Robert ^a   Kennelly, Sean P ^a   O'Neill, Desmond ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Alzheimer's disease; Amyloid; Pharmacological therapy

Indexed keywords

5,6 DIHYDRO 2 IMINO 3 METHYL 6 [4 [5 (1 PROPYNYL) 3 PYRIDINYL] 2 THIENYL] 4 PYRIMIDINONE; ADUCANUMAB; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; AZD 3293; BAPINEUZUMAB; BETA SECRETASE INHIBITOR; BIOLOGICAL MARKER; DONEPEZIL; IMMUNOGLOBULIN; MEMANTINE; PLACEBO; SOLANEZUMAB; TARENFLURBIL; TAU PROTEIN; UNCLASSIFIED DRUG; AMYLOID; CHOLINESTERASE INHIBITOR; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; APOE4 GENE; ARTICLE; CEREBROSPINAL FLUID; CHOLINERGIC ACTIVITY; CLINICAL EVALUATION; CONSTIPATION; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; EVENING DOSAGE; EXCITOTOXICITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERINSULINEMIA; HYPERTENSION; MUSCLE CRAMP; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; SOMNOLENCE; METABOLISM; PATHOPHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID; CHOLINESTERASE INHIBITORS; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 85014070035     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.16-3-247     Document Type: Article

References (74)

1. Brayne C, Davis D. Making Alzheimer's and dementia research fit for populations. Lancet 2012;380:1441-3.
2. Ngandu T, Lehtisalo J, Solomon A et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 2015;385:2255-63.
3. Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drugdevelopment pipeline: few candidates, frequent failures. Alzheimers Res Ther 2014;6:37.
4. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-6.
5. Murphy MP, LeVine H. Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis 2010;19:311-23.
6. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011;1:a006189.
7. Mandelkow EM, Mandelkow E. Tau in Alzheimer's disease. Trends Cell Biol 1998;8:425-7.
8. Bloom GS. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 2014;71:505-8.
9. Huang HCC, Jiang ZFF. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease. J Alzheimers Dis 2009;16:15-27.
10. Whitehouse PJ. The cholinergic deficit in Alzheimer's disease. J Clin Psychiatry 1998;59 Suppl 13:19-22.
11. Lipton SA. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism. Curr Alzheimer Res 2005;2:155-65.
12. Ravona-Springer R, Davidson M, Noy S. Is the distinction between Alzheimer's disease and vascular dementia possible and relevant? Dialogues Clin Neurosci 2003;5:7-15.
13. Hasnain M, Vieweg WV. Possible role of vascular risk factors in Alzheimer's disease and vascular dementia. Curr Pharm Des 2014;20:6007-13.
14. Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1999;13 Suppl 3:S115-23.
15. Petrovitch H, White LR, Izmirilian G et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol Aging 2000;21:57-62.
16. Tolppanen AMM, Solomon A, Soininen H, Kivipelto M. Midlife vascular risk factors and Alzheimer's disease: evidence from epidemiological studies. J Alzheimers Dis 2012;32:531-40.
17. O'Brien JT, Markus HS. Vascular risk factors and Alzheimer's disease. BMC Med 2014;12.
18. Valenti R, Pantoni L, Markus HS. Treatment of vascular risk factors in patients with a diagnosis of Alzheimer's disease: a systematic review. BMC Med 2014;12:160.
19. Lu FPP, Lin KPP, Kuo HKK. Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis. PLoS One 2009;4:e4144.
20. Luchsinger JA, Tang MXX, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004;63:1187-92.
21. Farris W, Mansourian S, Chang Y et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the betaamyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003;100:4162-7.
22. Craft S, Peskind E, Schwartz MW et al. Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998;50:164-8.
23. Banks WA, Jaspan JB, Huang W, Kastin AJ. Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin. Peptides 1997;18:1423-9.
24. Martinez A, Gil C, Perez DI. Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment. Int J Alzheimers Dis 2011;2011:280502.
25. Yarchoan M, Arnold SE. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes 2014;63:2253-61.
26. Craft S, Baker LD, Montine TJ et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69:29-38.
27. Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3.
28. Farrer LA, Cupples LA, Haines JL et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-56.
29. Kim J, Basak JM, Holtzman DM. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009;63:287-303.
30. Liu CCC, Liu CCC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 2013;9:106-18.
31. Morales I, Guzmán-Martínez L, Cerda-Troncoso C, Farías GA, Maccioni RB. Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci 2014;8:112.
32. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. Immunol Rev 2006;213:48-65.
33. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996;47:425-32.
34. Heneka M T, Carson M J, El Khoury J et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol 2015;14:388-405.
35. Jaturapatporn D, Isaac MGEKNG, McCleery J, Tabet N. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst Rev 2012;2: CD006378.
36. Breitner JC, Baker LD, Montine TJ et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement 2011;7:402-11.
37. Hensley K. Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. Alzheimers Dement 2010;21:1-14.
38. Salomone S, Caraci F, Leggio GMM et al. New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol 2012;73:504-17.
39. Manning FC. Tacrine therapy for the dementia of Alzheimer's disease. Am Fam Physician 1994;50:819-26.
40. National Institute for Health and Care Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. London: NICE, 2011. Available online at www.nice.org.uk/guidance/ta217/chapter/3-The-technologies [Accessed 22 December 2015].
41. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2003;(3): CD001190.
42. Robinson DM, Keating GM. Memantine: a review of its use in Alzheimer's disease. Drugs 2006;66(11):1515-34.
43. Areosa SA, Sherriff F. Memantine for dementia. Cochrane Database Syst Rev 2003;(3): CD003154.
44. Atri A, Molinuevo JL, Lemming O et al. Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther 2013;5:6.
45. Mufson EJ, Counts SE, Perez SE, Ginsberg SD. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev Neurother 2008;8:1703-18.
46. Ghezzi L, Scarpini E, Galimberti D. Disease-modifying drugs in Alzheimer's disease. Drug Des Dev Ther 2013;7:1471-8.
47. Vassar R. BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res Ther 2014;6:89.
48. Henley DB, May PC, Dean RA, Siemers ER. Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. Exp Opin Pharmacother 2009;10:1657-64.
49. Doody RS, Raman R, Farlow M et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 2013;369:341-50.
50. Green RC, Schneider LS, Amato DA et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009;302:2557-64.
51. Robinson SR, Bishop GM, Lee HGG, Münch G. Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol Aging 2004;25:609-15.
52. Loeffler DA. Intravenous immunoglobulin and Alzheimer's disease: what now? J Neuroinflammation 2013;10:70.
53. Prins ND, Scheltens P. Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future. Alzheimers Res Ther 2013;5; 56.
54. Salloway S, Sperling R, Fox NC et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:322-33.
55. Doody RS, Thomas RG, Farlow M et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med 2014;370:311-21.
56. Siemers ER, Sundell KL, Carlson C et al. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement 2016:12:110-20.
57. McCartney M. Margaret McCartney: The "breakthrough" drug that's not been shown to help in Alzheimer's disease. BMJ 2015;351:h4064.
58. National Institute on Aging. US Department of Health and Human Services. BIIB037 in prodromal or mild Alzheimer's disease. Bethesda, MD: NIA, 2016. Available online at www.nia.nih.gov/alzheimers/clinical-trials/biib037-prodromal-or-mild-alzheimers-disease [Accessed 5 April 2016]
59. Wischik CM, Harrington CR, Storey JM. Tau-aggregation inhibitor therapy for Alzheimer's disease. Biochem Pharmacol 2014;88:529-39.
60. Tariot PN, Aisen PS. Can lithium or valproate untie tangles in Alzheimer's disease? J Clin Psychiatry 2009;70:919-21.
61. Hampel H, Ewers M, Bürger K et al. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry 2009;70:922-31.
62. Wischik CM, Staff RT, Wischik DJ et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. J Alzheimers Dis 2015;44:705-20.
63. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18:351-7.
64. Anoop A, Singh PK, Jacob RS, Maji SK. CSF Biomarkers for Alzheimer's disease diagnosis. Int J Alzheimers Dis 2010;2010:606802.
65. Hertze J, Minthon L, Zetterberg H et al. Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. J Alzheimers Dis 2010;21:1119-28.
66. Engelborghs S, Le Bastard N. The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease. Mol Diagn Ther 2012;16:135-41.
67. Mosconi L, Berti V, Glodzik L et al. Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis 2010;20:843-54.
68. Mosconi L, Berti V, Glodzik L et al. Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis 2010;20:843-54.
69. Kennedy AM, Frackowiak RS, Newman SK et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Lett 1995;186:17-20.
70. Chételat G, Desgranges B, De La Sayette V et al. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003;60:1374-7.
71. Vandenberghe R, Adamczuk K, Van Laere K. The interest of amyloid PET imaging in the diagnosis of Alzheimer's disease. Curr Opin Neurol 2013;26:646-55.
72. Jack CR, Albert MS, Knopman DS et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:257-62.
73. Croisile B, Auriacombe S, Etcharry-Bouyx F, Vercelletto M. National Institute on Aging (US), Alzheimer Association. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia]. Rev Neurol (Paris) 2012;168:471-82.
74. Sloane PD, Zimmerman S, Suchindran C et al. The public health impact of Alzheimer's disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health 2002;23:213-31.